Does HRT raise risk of breast cancer in thin or obese women?
September 26th 2013A new registry-based study sheds light on patient factors that may influence risk of breast cancer associated with use of postmenopausal hormone replacement therapy (HRT)-including race, weight, and breast density. Findings from the report, published in The Journal of the National Cancer Institute, suggest the greatest association between HRT use and breast cancer in women with low/normal body mass index (BMI) and extremely dense breasts.
USPSTF updates guidelines on medication for breast cancer risk reduction
September 26th 2013In an update of its 2002 recommendation on use of medications for breast cancer risk reduction, the U.S. Preventive Services Task Force (USPSTF) is encouraging informed decision-making and cautioning against use of medications for prevention in women who are not at increased risk of the disease.
Top 4 ways to avoid malpractice suits
September 25th 2013For many physicians, no matter their specialty, the one thing that keeps them up at night is fear of medical malpractice lawsuits. Elisabeth Madden, partner at Lynch Gilardi and Grummer law firm in San Francisco, is an attorney with more than 20 years’ experience defending healthcare providers. In this article, based on a session at a recent conference for dermatologic surgeons, Ms. Madden explains some of the top ways surgeons can avoid medical malpractice lawsuits.
FDA prepares to approve Perjeta for use pre-surgery
September 19th 2013The Food and Drug Administration’s (FDA) advisory committee cleared the way for the approval of pertuzumab (Perjeta) to treat patients before they have surgery to remove their HER2-positive tumors. If approved, pertuzumab would be the first neoadjuvant drug approval for any form of cancer. The drug was already approved by the FDA for treatment of late-stage breast cancer last year.
Women who don’t get mammograms most likely to die of breast cancer
September 19th 2013A new multicenter analysis shows that most deaths from invasive breast cancer occur in women who don’t get routine mammograms. The findings, published in Cancer, point to a need to encourage routine screening in women younger than age 50.
Investigational fertility treatment approved by FDA
September 12th 2013The US Food and Drug Administration approved the new drug application (NDA) for Merck’s investigational fertility treatment corifollitropin alfa. Merck is seeking approval for the use of corifollitropin alfa in controlled ovarian stimulation (COS). If approved, the drug would be the first sustained follicular stimulant available in the United States.
Health Disparities in Uterine Fibroid Patients: a Q&A
September 9th 2013The findings of a recent study have shown that uterine fibroid tumors are more common and more severe in African American women compared with white women. Find out how you can better treat uterine fibroid tumors in this high-risk population.
Medicaid pays for nearly half of all US births
September 5th 2013In 2010, Medicaid financed 48% of all births in the United States, an increase of 19% in the proportion of all births covered by Medicaid in 2008. This finding, from a study published in the Sept. 2013 issue of the journal Women's Health Issues, adds to previous research showing that the numbers of women dependent on Medicaid for health care are growing.
NAMS updates recommendations for vulvovaginal atrophy
September 5th 2013Estrogen therapy is still the mainstay of therapy for moderate-to-severe symptoms and long-term studies on endometrial safety of local estrogen and ospemifene are lacking. Those are the key conclusions from an updated position statement on management of symptomatic vulvovaginal atrophy (VVA) in postmenopausal women issued by the North American Menopause Society (NAMS).